Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey.

Autor: Raveendran S; PatientsLikeMe, LLC, 6 Liberty Square, Suite 2602, Boston, MA, 02109, USA., Singh D; PatientsLikeMe, LLC, 6 Liberty Square, Suite 2602, Boston, MA, 02109, USA., Burke MC; PatientsLikeMe, LLC, 6 Liberty Square, Suite 2602, Boston, MA, 02109, USA., McAuliffe-Fogarty AH; PatientsLikeMe, LLC, 6 Liberty Square, Suite 2602, Boston, MA, 02109, USA., Parikh SV; Department of Psychiatry, Michigan Medicine, University of Michigan, 4250 Plymouth Road, Ann Arbor, MI, 48109, USA., McIntyre RS; Department of Psychiatry, University of Toronto and Centre for Addiction and Mental Health, 1451 Queen Street West, Toronto, ON, M6R 1A1, Canada.; University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst St., Toronto, ON, M5T 2S8, Canada., Roy A; Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave, Lexington, MA, 02421, USA., Martin M; Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave, Lexington, MA, 02421, USA., Chrones L; Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave, Lexington, MA, 02421, USA., Opler MGA; WCG Clinical Endpoint Solutions, 3 Park Avenue, New York, NY, 10016, USA.; PANSS Institute, 19 Crotty Court, Monroe, NY, 10950, USA., Blair C; Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave, Lexington, MA, 02421, USA. chris.blair@takeda.com., McCue M; Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Ave, Lexington, MA, 02421, USA.
Jazyk: angličtina
Zdroj: BMC psychiatry [BMC Psychiatry] 2023 Jun 26; Vol. 23 (1), pp. 464. Date of Electronic Publication: 2023 Jun 26.
DOI: 10.1186/s12888-023-04922-6
Abstrakt: Background: Major depressive disorder (MDD) is a recurrent psychiatric condition that presents challenges in responding to treatment and achieving long-term remission. To improve outcomes, a shared decision-making treatment approach with patient and healthcare practitioner (HCP) engagement is vital. PatientsLikeMe (PLM), a peer community of patients, provides information on MDD, symptoms, and treatment through forums and resources, helping patients stay engaged in their treatment journey. Data on PLM can be harnessed to gain insights into patient perspectives on MDD symptom management, medication switches, and treatment goals and measures.
Methods: This ongoing, decentralized, longitudinal, observational, prospective study is being conducted using the PLM platform in two parts, enrolling up to 500 patients with MDD in the United States aged ≥ 18 years to compare vortioxetine with other monotherapy antidepressants. The first qualitative component consists of a webinar and discussion forum with PLM community members with MDD, followed by a pilot for functionality testing to improve the study flow and questions in the quantitative survey. The quantitative component follows on the PLM platform, utilizing patient-reported assessments, over a 24-week period. Three surveys will be conducted at baseline and weeks 12 and 24 to collect data on patient global impression of improvement, depression severity, cognitive function, quality of life (QoL) and well-being, medication satisfaction, emotional blunting, symptoms of anhedonia and resilience, as well as goal attainment. Quantitative results will be compared between groups. The qualitative component is complete; patient recruitment is underway for the quantitative component, with results expected in late 2023.
Discussion: These results will help HCPs understand patient perspectives on the effectiveness of vortioxetine versus other monotherapy antidepressants in alleviating symptoms of MDD and improvements in QoL. Data from the PLM platform will support a patient goal-based treatment approach, as results can be shared by patients with their HCPs, providing them with insights on patient-centric goals, treatment management and adherence, as well as allowing them to observe changes in patient-related outcomes scores. Findings from the study will also help to optimize the PLM platform to build scalable solutions and connectivity within the community to better serve patients with MDD.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje